Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...
A comprehensive study of effective and resistant responses to a kidney cancer anti-PD-1 therapy found specific immune ...
IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...
During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...
GlobalData on MSN2d
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancerThe US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback